Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial on the Efficacy and Safety of Changji'an Capsules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver-Qi Invading Spleen Syndrome)

NCT07610434 is registered in ClinicalTrials.gov with Beijing Hospital of Traditional Chinese Medicine as lead sponsor.

NCT NCT07610434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07610434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial on the Efficacy and Safety of Changji'an Capsules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver-Qi Invading Spleen Syndrome)
Lead sponsor
Beijing Hospital of Traditional Chinese Medicine
Phase
Phase 3
Overall status
Not yet recruiting
Start date
May 31, 2026
Completion date
May 31, 2028
Enrollment
636 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

ibs, diarrhea predominant